Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/222019 International Application No.: PCT/KR2018/006327
Publication Date: 06.12.2018 International Filing Date: 01.06.2018
C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
[IPC code unknown for C07K 16/28][IPC code unknown for A61K 39]
서울대학교 산학협력단 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION [KR/KR]; 서울시 관악구 관악로 1 1, Gwanak-ro Gwanak-gu Seoul 08826, KR
박정규 PARK, Chung Gyu; KR
김정식 KIM, Jung Sik; KR
김순웅 KIM, Soon Woong; KR
Priority Data:
(KO) 신규한 항-CD40 항체 및 이의 용도
(EN) The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.
(FR) La présente invention concerne de nouveaux anticorps anti-CD40 et leur utilisation et, plus particulièrement, l'invention concerne une composition pharmaceutique pour traiter ou prévenir des maladies auto-immunes et une composition pour inhiber le rejet immunitaire pendant une transplantation d'organe, les deux compositions contenant, en tant que principe actif, de nouveaux anticorps anti-CD40 qui se lient de manière spécifique à un nouvel épitope de CD40. Les nouveaux anticorps anti-CD40 selon la présente invention ciblent directement CD40, mais pas les ligands CD40, et bloquent la signalisation de CD40-CD154 sans stimuler les plaquettes de manière à présenter d'excellents effets antagonistes, ce qui les rend appropriés pour une utilisation en tant que préparation efficace dans le traitement de maladies auto-immunes et l'inhibition du rejet de transplantation d'organe.
(KO) 본 발명은 신규한 항-CD40 항체 및 이의 용도에 관한 것으로, 보다 상세하게는 CD40의 신규 에피토프에 특이적으로 결합하는 신규한 항-CD40 항체를 유효 성분으로 포함하는 자가면역질환의 치료 또는 예방용 약학적 조성물 및 장기이식시 면역거부반응 억제용 조성물을 제공한다. 본 발명의 신규한 항-CD40 항체는 CD40 리간드가 아닌 CD40을 직접 타겟으로 하며, 혈소판을 자극하지 않으면서 CD40-CD154 신호전달을 차단하여 탁월한 길항 효과를 나타내므로 자가면역질환의 치료 및 장기이식 거부반응 억제에 효과적인 제제로 활용될 수 있을 것으로 기대된다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)